US EditionFDA Approves Roche’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Lurbinectedin plus atezolizumab reduces progression or death risk by 46% and death risk by 27%, marking the first FDA-approved first-line maintenance combo for ES-SCLC.
16 Articles
16 Articles
Globe Newswire
The Manila TimesFDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1First and only combination...
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for Zepzelca®...
FDA approves Roches Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1 First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC2 Regimen recommended in National Comprehensive Cancer Network® […] The post FDA approves Roches Tecentriq plus lurbinectedin as first-line maintenance therapy for…
PharmaMar's shares were more than 7% in this Friday's stock market start, after it became known that the U.S. Food and Drug Administration (FDA) has given 'green light' to the combination of its drug Zepzelca (lurbinectedin) with atezolizumab (Tecentriq) as a first-line maintenance treatment for advanced-stage small cell lung cancer. Thus, the Spanish pharmaceutical company advanced by 7.42% in the Continuo Market, to put its titles at 99.9 euro…
PharmaMar has been approved by the United States Food and Drug Administration (FDA) to combine its drug Zepzelca (lurbinectedine) with atezolizumab (Tecentriq) as a first-line maintenance treatment for advanced small cell lung cancer (SCLC).
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
